로딩 중…
지수 로딩 중…
ToolGen
199800· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩29,100-0.34%
2026-11-02
Financials
Valuation Metrics
ToolGen's Market Cap is ₩2844B. At end of 2025 it was ₩5640B. Ranked #625 of 2,410 in KR market (top 26%), #257 of 1,631 on KOSDAQ (top 16%), #67 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 284.44B KRW | KR#625/2,410 Sec#67/231 |
| Revenue | 1.91B KRW | KR#2,373/2,410 Sec#216/231 |
| Net Income | -39.12B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 61.65B KRW | KR#2,084/2,410 Sec#182/231 |
| Net Assets | 55.85B KRW | KR#1,828/2,410 Sec#154/231 |
| Employees | 82 | KR#1,789/2,410 Sec#148/231 |
| Value | ||
| P/B | 5.09x | KR#2,268/2,410 Sec#195/231 |
| P/S | 148.72x | KR#2,387/2,410 Sec#215/231 |
| FCF Yield | -7.27% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -70.05% | KR#2,310/2,410 Sec#208/231 |
| ROA | -63.45% | KR#2,368/2,410 Sec#219/231 |
| Op. Margin | -1246.31% | KR#2,369/2,410 Sec#214/231 |
| Revenue Growth | 116.74% | KR#70/2,410 Sec#12/231 |
| Earnings Growth | -558.53% | KR#1,305/2,410 Sec#91/231 |
| Financial Health | ||
| Debt Ratio | 10.39% | KR#151/2,410 Sec#31/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -20.67B KRW | KR#1,891/2,410 Sec#181/231 |
| Cash | 9.48B KRW | KR#1,721/2,410 Sec#146/231 |
| Current Ratio | 6.10x | KR#208/2,410 Sec#41/231 |
| Performance | ||
| 1Y Return | -49.04% | KR#1,933/2,410 Sec#169/231 |
| 1M Return | -15.77% | KR#1,939/2,410 Sec#194/231 |
| From 52W High | -79.19% | KR#2,277/2,410 Sec#207/231 |
| 1Y MDD | -79.53% | KR#2,270/2,410 Sec#201/231 |
| Trading | ||
| Volume | 19,522 shares | KR#1,323/2,410 Sec#133/231 |
| Trading Value | 562.1M KRW | KR#639/2,410 Sec#66/231 |
| Foreign Own. | 2.05% | KR#1,601/2,410 Sec#153/231 |
| Per Share | ||
| EPS | -4,002 KRW | KR—/2,410 Sec—/231 |
| BPS | 5,714 KRW | KR#1,406/2,410 Sec#101/231 |
Company Info
동사는 1999년 유전자 교정 플랫폼 사업을 위해 설립되어 2021년 코스닥 시장에 상장함. ZFN, TALEN, CRISPR/Cas9 등 유전자가위를 독자 개발한 세계 유일 기업으로 CRISPR 유전자가위의 진핵세포 작동을 세계 최초로 입증한 특허 보유, 특허 388건 확보함. 유전자 교정 플랫폼 기술의 원천특허 기반으로 특허 수익화, 치료제 및 종자 관련 연구개발을 진행하며 질병 없는 건강 및 풍요로운 삶을 목표로 하고 있음. 툴젠는 1999년에 설립되었으며 서울특별시 강서구에 본사를 두고 있습니다.